Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model

Molecular Therapy

Volumn 7, Issue 6, 2003, Pages 741-747

  Miller, Cathie G ^a,b   Fraser, Nigel W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

HSV; Immune response; Melanoma

Indexed keywords

CANCER ANTIBODY; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; BRAIN METASTASIS; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; FEMALE; HERPES SIMPLEX VIRUS 1; IMMUNE RESPONSE; INTRACRANIAL TUMOR; LYMPHOCYTE PROLIFERATION; MELANOMA; MOUSE; NONHUMAN; REVIEW; VIRUS ATTENUATION; VIRUS INFECTION; VIRUS MUTANT; VIRUS NEUTRALIZATION;

ANIMALIA; HERPES; HUMAN HERPESVIRUS 1;

EID: 0038150551     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(03)00120-5     Document Type: Article

References (51)

1. Cairncross, J., Kim, J., and Posner, J. (1980). Radiation therapy for brain metastasis. Ann. Neurol. 7: 529-541.
2. Posner, J. B. (1992). Management of brain metastases. Rev. Neurol. 148: 477-487.
3. Chidel, M., Suh, J., and Barnett, G. (2000). Brain metastases: presentation, evaluation, and management. Cleveland Clin. J. Med. 67: 120-127.
4. Akslen, L. A., Howe, L. M., and Hartveit, F. (1987). Metastatic distribution in malignant melanoma. Invasion Metastasis 7: 253-263.
5. Landis, S., Murray, T., Bolden, S., and Wingo, P. (1998). Cancer statistics. CA Cancer J. Clin. 49: 8-31.
6. Fernandez-Vicioso, E., Suh, J. H., Kupelian, P. A., Sohn, J. W., and Barnett, G. H. (1997). Analysis of prognostic factors for patients with single brain metastasis treated with stereotactic radiosurgery. Radiat. Oncol. Invest. 5: 31-37.
7. Andreansky, S., et al. (11997). Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res. 57: 1502-1509.
8. Boviatsis, E. J., et al. (1994). Long-term survival of rats harboring brain neoplasms treated with a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. 54: 5745-5751.
9. Coukos, G., et al. (2000). Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer Gene Ther. 7: 275-283.
10. Pyles, R. B., Warnick, R. E., Chalk, C. L., Szanti, B. E., and Parsek, L. M. (1997). A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum. Gene Ther. 8: 533-544.
11. Randazzo, B. P., et al. (1995). Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology 211: 94-101.
12. Miller, C., and Fraser, N. (2000). Role of the immune response during neuro-attenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model. Cancer Res. 60: 5714-5722.
13. Miller, C. G., Krummenacher, C., Eisenberg, R. J., Cohen, G. H., and Fraser, N. W. (2001 ). Development of a syngenic murine B16 cell line-derived melanoma susceptible to destruction by neuroattenuated HSV-1. Mol. Ther. 3: 160-168.
14. Yoon, S. S., Carroll, N. M., Chiocca, E. A., and Tanabe, K. K. (1998). Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector. Ann. Surg. 228: 366-374 [Published erratum appears in Ann. Surg., 1998, 228(5): following table of contents].
15. Yazaki, T., Manz, H. J., Rabkin, S. D., and Martuza, R. L. (1995). Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res. 55: 4752-4756.
16. Toda, M., Martuza, R. L., Kojima, H., and Rabkin, S. D. (1998). In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J. Immunol. 160: 4457-4464.
17. Todo, T., Martuza, R., Rabkin, S., and Johnson, P. (2001). Oncolytic herpes simplex virus vector with enhanced mHC class I presentation and tumor cell killing. Proc. Natl. Acad. Sci. USA 98: 6396-6401.
18. Ackermann, M., Longnecker, R., Roizman, B., and Pereira, L. (1986). Identification, properties, and gene location of a novel glycoprotein specified by herpes simplex virus 1. Virology 150: 207-220.
19. Chou, J., Kern, E. R., Whitley, R. J., and Roizman, B. (1990). Mapping of herpes simplex virus neurovirulence to gamma 1 34.5, a gene nonessential for growth in culture. Science 252: 1262-1266.
20. McGeoch, D. J., and Barnett, B. C. (1991). Neurovirulence factor. Nature 353: 609.
21. MacLean, A. R., Ul-Fareed, M., Robertson, L., Harland, J., and Brown, S. M. (1991). Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J. Gen. Virol. 72: 631-639.
22. McLean, C. A., Efstathiou, S., Elliot, M. L., Jamieson, F. E., and McGeoch, D. J. (1991). Investigation of herpes simplex virus type 1 genes encoding multiply inserted membrane proteins. J. Gen. Virol. 72: 897-906.
23. Spivack, J. G., and Fraser, N. W. (1987). Detection of herpes simplex virus type 1 transcripts during latent infection in mice. J. Virol. 61: 3841-3847 [Published erratum appears in J. Virol., 1988, 62: 663].
24. Yasamura, Y., and Sato, G. H. (1966). Establishment of four functional, clonal strains of animal cells in culture. Science 154: 1186-1189.
25. Molner-Kimber, K., et al. (1998). Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum. Gene Ther. 9: 2121-2133.
26. Jia, W. W.-G., McDermott, M., Goldie, J., Cynader, M., Tan, J., and Tufaro, F. (1994). Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type I. J. Natl. Cancer Inst. 86: 1209-1215.
27. Toda, M., Rabkin, S. D., and Martuza, R. L. (11998). Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum. Gene Ther 9: 2177-2185.
28. Chen, B., et al. (2000). Evaluation of combined vaccinia virus-mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model. Cancer Gene Ther. 7: 1437-1447.
29. Krauzewicz, N., and Griffin, B. (2000). Polyoma and papilloma virus vectors for cancer gene therapy. In Cancer Gene Therapy: Past Achievements and Future Challenges (Habib, Ed.), pp. 73-82. Kluwer Academic/Plenum, New York.
30. Pizzato, M., et al. (1998). Production and characterization of a bicistronic Moloney-based retroviral vector expressing human interleukin 2 and herpes simplex virus thymidine kinase for gene therapy of cancer. Gene Ther. 5: 1003-1007.
31. Nanda, D., Vogels, R., Havenga, M., Avezaat, C., Bout, A., and Smitt, P. S. (2001). Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res. 61: 8743-8750.
32. Zheng, H., Palese, P., and Garcia-Sastre, A. (2000). Antitumor properties of influenza virus vectors. Cancer Res. 60: 6972-6976.
33. Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D. D., and Kirn, D. H. (1997). ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic, agents. Nat. Med. 3: 639-645.
34. Reid, T., et al. (2002). Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1 520): phase II viral, immunologic, and clinical endpoints. Cancer Res. 62: 6070-6079.
35. Habib, N. A., et al. (2002). Assessment of growth inhibition and morphological changes in in vitro and in vivo hepatocellular carcinoma models post treatment with dl1 520 adenovirus. Cancer Gene Ther. 9: 414-420.
36. Johnson, L., et al. (2002). Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 1: 325-337.
37. Portella, G., Scala, S., Vitagliano, D., Vecchio, G., and Fusco, A. (2002). ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines. J. Clin. Endocrinol. Metab. 87: 2525-2531.
38. Petit, T., et al. (2002). Efficient induction of apoptosis by ONYX-015 adenovirus in human colon cancer cell lines regardless of p53 status. Anti Cancer Drugs 13: 47-50.
39. Geoerger, B., et al. (2002). Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res. 62: 764-772.
40. Brown, S. M., Harland, J., MacLean, A. R., Podlech, J., and Clements, J. B. (1994). Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5-negative herpes simplex virus types 1 and 2. J. Gen. Virol. 75: 2367-2377.
41. Chou, J., and Roizman, B. (1994). Herpes simplex virus 1 γ34.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage. Proc. Natl. Acad. Sci. USA 91: 5247-5251.
42. Whitley, R. J., Kern, E. R., Chatterjee, S., Chou, J., and Roizman, B. (1993). Replication, establishment of latency, induced reactivation of herpes simplex virus γ134.5 deletion mutants in rodent models. J. Clin. Invest. 91: 2837-2843.
43. Valyi-Nagy, T., et al. (1994). The herpes simplex virus type 1 strain 17+ gamma 34.5 deletion mutant 1716 is avirulent in SCID mice. J. Gen. Virol. 75: 2059-2063.
44. Markert, J., et al. (2000). Conditionally replicating herpes simplex virus mutant G207 for the treatment of malignant glioma: results of a phase 1 trial. Gene Ther. 7: 867-874.
45. Rampling, R., et al. (2000). Toxicity evaluation of replication competent herpes simplex virus (IC34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 7: 859-866.
46. Todo, T., et al. (1999). Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum. Gene Ther. 10: 2741-2755.
47. Toyoizumi, T., Mick, R., Abbas, A. E., Kang, E. H., Kaiser, L. R., and Molnar-Kimber, K. L. (1999). Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum. Gene Ther. 10: 3013-3029.
48. Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., and Martuza, R. L. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1: 938-943.
49. + T cell response. J. Exp. Med. 187: 341-348.
50. Hill, A., et al. (1995). Herpes simplex virus turns off the TAP to evade host immunity. Nature 375: 411-415.
51. Fruh, K., et al. (1995). A viral inhibitor of peptide transporters for antigen presentation. Nature 375: 415-418.